天弘沪深港创新药50ETF联接C(014565)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
37,280,224.60 |
-9,369,950.03 |
-21,732,978.76 |
-11,409,447.14 |
| 利息合计 |
90,726.06 |
70,386.43 |
35,336.25 |
65,745.82 |
| 其中:存款利息收入 |
90,726.06 |
70,386.43 |
35,336.25 |
65,745.82 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-595,214.78 |
-9,557,752.14 |
-6,550,261.72 |
-651,732.87 |
| 其中:股票投资收益 |
167,572.33 |
57,302.76 |
-241,343.35 |
-37,042.78 |
| 基金投资收益 |
-794,141.72 |
-9,655,675.38 |
-6,330,908.52 |
-628,965.04 |
| 债券投资收益 |
3,219.45 |
3,772.03 |
2,504.04 |
175.22 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
28,135.16 |
36,848.45 |
19,486.11 |
14,099.73 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
37,749,029.57 |
82,899.71 |
-15,237,147.87 |
-10,884,445.92 |
| 其他收入 |
35,683.75 |
34,515.97 |
19,094.58 |
60,985.83 |
| 费用 |
157,245.30 |
260,640.74 |
136,521.91 |
151,470.99 |
| 管理人报酬 |
29,412.65 |
25,357.18 |
13,134.29 |
21,586.94 |
| 基金托管费 |
5,882.44 |
5,071.45 |
2,626.86 |
4,317.41 |
| 销售服务费 |
62,420.01 |
109,769.96 |
56,097.75 |
85,504.79 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
59,530.20 |
120,442.15 |
64,663.01 |
40,061.85 |
| 利润总额 |
37,122,979.30 |
-9,630,590.77 |
-21,869,500.67 |
-11,560,918.13 |